Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors - Wikidata - wikimedia - TriplyDB

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q33412724

about

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Epigenetic treatment of solid tumours: a review of clinical trials Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.Dinutuximab and Panobinostat The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay Natural product and natural product derived drugs in clinical trials.Panobinostat: first global approval.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors.Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

P2860

Q26771601-EB23EE44-8AD7-4950-9042-118AD6213C85 Q26773803-7C6ADAE9-614E-452B-A810-FDE5C91B4419 Q26799387-87A685C7-DFEA-477A-92F0-82A63DB2FC5B Q33689457-7E4DBABE-40CD-4DF3-8373-36483C0856EC Q34135528-3B2ED6D0-099F-467D-8DF3-ECD29674C759 Q36125976-C461A570-882A-4FE4-86E5-1137183F99AB Q36192000-018C7AD9-E6A0-4587-B484-91E6EF10C828 Q36572408-DD1CD6F4-1DDD-41AB-893F-88894092A0C5 Q37034469-15B9B5F5-1F11-484A-853C-89A72A38367F Q37131708-482F70CB-2812-44E7-A57C-8CAFB8832285 Q37578338-DF909673-1F36-427B-B7B1-AF576FAA81A6 Q38247457-FCAB0116-2101-41F5-9ED7-C14056C349F2 Q38403118-40976FE4-733A-41F8-8278-060FB97575EF Q38925022-2E2D4AF7-FC7E-4147-B282-EF251AC70EE3 Q39288497-65FC1325-6080-451E-81D1-664F63117CA6 Q47097647-5B8918F4-83C3-4E80-94DA-6B8803D9872D Q47355982-FC555403-8D36-4044-819F-B364DEBD7807 Q47432725-8298A775-A70B-4E53-86FD-E982A530FBCD Q47895606-FB254D28-2C69-4113-A12C-0330763C4DD1 Q52689154-B2A99070-F961-493F-9BD0-CE90D6BEC18B Q57696000-75139193-96CD-41F7-AE58-FCD5DA930B1E

P2860

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q33412724

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I study of panobinostat ...... astrointestinal stromal tumors

@ast

Phase I study of panobinostat ...... astrointestinal stromal tumors

@en

type

label

Phase I study of panobinostat ...... astrointestinal stromal tumors

@ast

Phase I study of panobinostat ...... astrointestinal stromal tumors

@en

prefLabel

Phase I study of panobinostat ...... astrointestinal stromal tumors

@ast

Phase I study of panobinostat ...... astrointestinal stromal tumors

@en

P1433

Q33412724-ECFF9B4B-27D1-44A8-B83B-CEE689864BDA

P1476

Q33412724-3DB8F7D6-2C79-4A23-B82C-01D59737D4CA

P2093

Q33412724-13D61CAF-CEAF-4EC5-997C-5DA389928C7B

Q33412724-1964DE18-D2DB-4861-884F-6EB4AB65DACD

Q33412724-24F4FFB1-9A45-48DA-BC27-AF11411FD986

Q33412724-389E637D-249E-44CD-8031-36D8CE2F51B6

Q33412724-5957AE0B-CC69-4A6C-BFDF-BC2DDAC475EF

Q33412724-84156250-3AF8-416B-9037-9A878F0C1479

Q33412724-900F1470-879B-40D5-9D82-BF0944D45643

Q33412724-9B3865B3-087D-4D8C-AE61-725871AA7EE9

Q33412724-B792AFB2-BCA1-476E-8DF8-98E806347A5C

Q33412724-DCD66533-EF2A-40C1-B3A3-0FD46E7BE07D

P2860

Q33412724-0DDA7FF1-F56D-41A3-92E4-CB7F01B79B42

Q33412724-13D65CB3-146A-4791-BA4E-CB36A94977C5

Q33412724-2143AE58-52D7-4FB1-8656-BED885EDCD32

Q33412724-2974A213-9346-4281-8C8F-A93C8E1FDD61

Q33412724-2B5F3544-FBF0-43DB-9200-323D9AD31ED1

Q33412724-346E17EF-63F1-4937-8FB9-C27D52501479

Q33412724-35D8574F-A83A-45DD-9E3D-6E218F2AAB22

Q33412724-5846EAA5-CB9D-4902-AEF9-E8ADE8337A01

Q33412724-598B7F7E-56E2-42E6-8C0A-2AE4582CEFF1

Q33412724-5F687FB1-09FB-4A08-B67A-C669DE3041A4

P2888

Q33412724-A744E71E-EB6A-4B7D-B5FC-55AE738E75A6

P304

Q33412724-D1DB0C3E-7193-4EB9-89BF-346BB1EDE199

P31

Q33412724-DE277783-7973-476A-B940-868CD3BF5B2F

P356

Q33412724-35F2D6D3-6E2E-410B-9DE4-B15DE66C4317

P407

Q33412724-02810581-9047-4197-AB3B-25A7C188B744

P433

Q33412724-DAB0E59C-93C6-42FD-89D4-5C7CCB9315A1

P478

Q33412724-60EC1A7F-0CE4-430A-8E8B-8C7723E03A54

P50

Q33412724-2A6CF04E-DB6F-4EFE-A2F3-7D6C963C7A03

Q33412724-2A9E5226-D73C-43D2-9B9C-F1660FEA4768

Q33412724-EA401B39-CF3A-4E40-999A-9882AC1AA6AF

P577

Q33412724-CD9003CD-6742-41EF-ADD6-B0B886DD044B

P5875

Q33412724-8D0E222D-74AA-4302-9E31-20F82CB934D3

P6179

Q33412724-74ED407F-9D76-4F59-8E36-EA8D52F4F071

P698

Q33412724-710CDE66-56F7-4486-92AF-37259BF8DAFD

P932

Q33412724-05569149-6D38-493C-A42D-3D00F2B5BC4B

P356

P1433

British Journal of Cancer

P1476

Phase I study of panobinostat ...... astrointestinal stromal tumors

@en

P2093

A Pustowka

http://www.w3.org/2001/XMLSchema#string

A Reichardt

http://www.w3.org/2001/XMLSchema#string

D Pink

http://www.w3.org/2001/XMLSchema#string

E Bock

http://www.w3.org/2001/XMLSchema#string

F Grabellus

http://www.w3.org/2001/XMLSchema#string

M Ahrens

http://www.w3.org/2001/XMLSchema#string

M E Scheulen

http://www.w3.org/2001/XMLSchema#string

M Hoiczyk

http://www.w3.org/2001/XMLSchema#string

M Schuler

http://www.w3.org/2001/XMLSchema#string

P Reichardt

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

P2888

P304

1155-1162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.826

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

James Nagarajah

Thomas Mühlenberg

Sebastian Bauer

P577

2014-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259769489

http://www.w3.org/2001/XMLSchema#string

P6179

1001000584

http://www.w3.org/2001/XMLSchema#string

P698

24434430

http://www.w3.org/2001/XMLSchema#string

P932

3950855

http://www.w3.org/2001/XMLSchema#string